unknown
Stage
About
Caldan Therapeutics is a university spin-out developing novel therapeutics that target free fatty acid receptors for metabolic diseases. Its lead programme is a selective FFA4 (GPR120) agonist aimed at treating Non-Alcoholic Steatohepatitis (NASH).
Explore Caldan Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.